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Abstract 30 
Neuromodulators are endogenous neurochemicals that regulate biophysical and 31 
biochemical processes, which control brain function and behaviour, and are often the targets 32 
of neuropharmacological drugs. Neuromodulator effects are generally complex partly due to 33 
the involvement of broad innervation, co-release of neuromodulators, complex intra- and 34 
extra-synaptic mechanism, existence of multiple receptor subtypes, and high interconnectivity 35 
within the brain. In this work, we propose an efficient yet sufficiently realistic computational 36 
neural modelling framework to study some of these complex behaviours. Specifically, we 37 
propose a novel dynamical neural circuit model that integrates the effective neuromodulator-38 
induced currents based on various experimental data (e.g. electrophysiology, 39 
neuropharmacology and voltammetry). The model can incorporate multiple interacting brain 40 
regions including neuromodulator sources, simulate efficiently, and easily extendable to large-41 
scale brain models e.g. for neuroimaging purposes. As an example, we model a network of 42 
mutually interacting neural populations in the lateral hypothalamus, dorsal raphe nucleus and 43 
locus coeruleus, which are major sources of neuromodulator orexin/hypocretin, serotonin and 44 
norepinephrine/noradrenaline, respectively, and which play significant roles in regulating 45 
many physiological functions. We demonstrate that such model can provide predictions of 46 
systemic drug effects of the popular antidepressants (e.g. reuptake inhibitors), 47 
neuromodulator antagonists, or their combinations. Finally, we developed user-friendly 48 
graphical interface software for model simulation and visualization for both fundamental 49 
sciences and pharmacological studies.  50 
 51 
 52 
Keywords: Computational neural circuit models, neuromodulators, neuropharmacology, 53 
orexin/hypocretin, serotonin, norepinephrine/noradrenaline 54 
 55 
 4 | P a g e  
 
1. Introduction 56 
Neuronal activities, through the firing of action potentials, and synaptic transmissions can 57 
be modulated by endogenous neurochemicals called neuromodulators, acting through 58 
biophysical and biochemical processes (1, 2). These neuromodulators are released by a 59 
distinct population of neurons, and the neuromodulators act on specific receptors which 60 
are distributed throughout the brain (3). Major neuromodulators include serotonin, 61 
dopamine, norepinephrine (or noradrenaline), acetylcholine, orexin (or hypocretin), 62 
endorphins, and octopamine (3). As a consequence of neuromodulation, neural circuit 63 
function can be altered, which in turn can affect cognition, mood and behaviour (3). In 64 
neuropharmacological drug treatment of neurological and neuropsychiatric illnesses, the 65 
monoaminergic systems (especially that of serotonin, dopamine and norepinephrine) are 66 
often targeted (4). These are achieved, for example, by altering the affinity of the 67 
associated receptors that influences the release and reuptake mechanism of the 68 
monoaminergic systems (5, 6) . As neuromodulators can also influence the biophysical 69 
properties of the neurons and synapses via multiple receptors with differential affinities, 70 
the complexity level in a neuronal circuit function can be substantial (7, 8). Experimental 71 
work often focuses on a specific brain region or system (e.g. certain receptor subtype) or 72 
employs a specific experimental methodology specific to the single level of biological 73 
organization (e.g. whole-cell recording at the neuronal level or voltammetric recording at 74 
specific brain region). Thus, it is difficult to reconcile their systemic implications.  75 
 76 
Sufficiently realistic computational neural models can help to integrate various data types 77 
from different studies, and can also generate testable predictions. However, modelling the 78 
detailed biophysical effects of neuromodulators model can be complex and 79 
computationally costly (9-11). In particular, neuromodulation often involves intracellular 80 
signalling processes at the presynaptic and postsynaptic sites, and can subsequently 81 
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affect neuronal firing activities (12, 13). Hence, such computational models that 82 
incorporate these biological processes can be time-consuming to develop, and with the 83 
multiple model parameters and equations, computationally intensive to evaluate while 84 
posing a considerable challenge in scalability.  85 
 86 
In this work, we propose a novel neural circuit modelling framework to circumvent such 87 
difficulties. To develop a scalable model, we make use of neural population averaged 88 
activity (mean-field like) or firing-rate type models that describe how the neural population 89 
activities depend on the averaged effective neuromodulator induced currents. The latter 90 
are determined by neuromodulators’ concentration levels and the corresponding receptors 91 
affinity. Compared to other more abstract population averaged firing-rate type models (14-92 
17), our model parameters describing the input-output functions and temporal dynamics 93 
are informed and constrained by data integrated from a variety of experiments, which 94 
include electrophysiology, neuropharmacology, radioimmunoassay, voltammetry and 95 
microdialysis.  96 
 97 
We discuss such modelling approach in the context of developing and simulating a neural 98 
circuit model interconnected among the dorsal raphe nucleus (DRN), locus coeruleus (LC) 99 
and lateral hypothalamus areas (LHA), which are major sources of the important 100 
neuromodulators serotonin (5-HT), norepinephrine (NE), and orexin, respectively. The 101 
motivations for selecting these brain systems to model are that they are important in 102 
regulating physiological functions especially in arousal, are known to interact mutually with 103 
each other, and are the targets of several drugs (13, 18-21). In particular, the neuropeptide 104 
Ox is known to play an important role in energy homeostasis, food intake and appetite 105 
regulation, neuroendocrine functions and sleep-wake regulation (22-24). The monoamine 106 
NE is suggested to be responsible for numerous functions including stress response, 107 
attention, emotion, motivation, decision-making, learning, memory, and regulation of sleep 108 
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(e.g. REM) (25-30), while the monoamine 5-HT can affect several physiological functions 109 
that includes eating behaviour, emotion, and sleep regulation (31-33). Abnormal 5-HT or 110 
NE levels are implicated in mood disorders and anxiety (18, 34).  111 
 112 
 113 
Figure 1. Interactions among three brain regions, which are sources of 114 
neuromodulators. LHA: lateral hypothalamus; DRN: dorsal raphe nucleus; LC: locus 115 
coeruleus. Ox: orexin; 5-HT: serotonin. Arrows: effective excitatory connections between 116 
any two areas; circles: inhibitory connections. Different colours denote different brain 117 
areas. Small fonts denote receptor subtypes at the target sites (35-39).  118 
 119 
The overlapping roles of these neuromodulators are not surprising, given their mutual 120 
interconnectivity, and any targeted neurons could themselves be sources of 121 
neuromodulators (Fig. 1). We have also purposefully selected the Ox system as a case 122 
study to demonstrate how we can model a neural system that may not be well 123 
characterised (as compared to NE).  124 
 125 
A comprehensive, biologically faithful, yet efficient computational model at the neural 126 
circuit level would enable us to conveniently evaluate, account and predict, at a systems 127 
level, important measurable variables such as the concentration levels of the 128 
neuromodulators, the neural population firing rate activities, the effects of individual or 129 
combined drugs (e.g. reuptake inhibitors or antagonists), and their interdependencies.   130 
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The organization of the rest of the paper is as follows. We first describe the general 131 
modelling framework. Then, as an example, we demonstrate the steps in modelling three 132 
mutually interacting brain regions and discuss the simulation results including drug effects. 133 
Next, we describe our user-friendly software for simulating and visualizing the behaviour 134 
of such models. Finally, we summarise the results and discuss the implications of this 135 
study.  136 
 137 
2. Results  138 
2.1. An integrated modelling framework 139 
To develop a biologically compatible neural circuit model would require knowledge of 140 
electrophysiological properties of the composing neurons in a specific brain region, and 141 
the nature of the interactions among themselves and with other neuronal groups. This can 142 
include neurons which themselves release neuromodulators. Modelling the release-and-143 
reuptake/decay dynamics of the extracellular concentrations of the neuromodulators would 144 
require information inferred from in-vivo voltammetry or microdialysis studies at the 145 
targeted sites under neuronal stimulation. We would also need to know how the variation 146 
in neuromodulator concentration can in turn affect neural firing rate activities via 147 
neuromodulator induced currents, hence requiring knowledge of firing rate-148 
neuromodulator concentration or firing rate-current relationships (Fig. 2). These 149 
neuromodulator induced currents typically involve relatively slow metabotropic G-protein-150 
coupled receptor (GPCR) types, e.g. G-protein-coupled inwardly-rectifying potassium 151 
(GIRK) or transient receptor potential (TRP) type cation currents (37, 38), on targeted 152 
neurons, which alter the neuronal firing rate activities. As discussed, explicitly modelling 153 
such signalling pathway mechanisms can be complex and computationally intensive if 154 
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large-scale neural circuits are involved. To circumvent such challenges, we turn to 155 
phenomenological yet biologically faithful models to mimic the overall effects.  156 
 157 
 158 
 159 
Figure 2. Incorporating afferent currents from neuromodulator concentration levels. 160 
[𝑦1] … [𝑦𝑛] denote the different neuromodulator concentrations. 𝑖 represents a particular 161 
targeted brain region. 𝐼𝑗→𝑖 is the corresponding induced currents to region 𝑖. 𝐼𝑇𝑜𝑡𝑎𝑙,𝑖 is the 162 
total afferent current and 𝑓𝑖 is the firing frequency in region 𝑖. For example, [𝑦1] and [𝑦2] 163 
may be the concentration levels of serotonin [5 − 𝐻𝑇] and norepinephrine [𝑁𝐸], and 𝑖 can 164 
be the lateral hypothalamus LHA. The big arrow denotes “closing the loop” in the modelling 165 
process.  166 
 167 
To begin the modelling process, we first model the neural activity for each brain region 168 
using neural population averaged activity (40). Since the time-constant of the typical neural 169 
population firing-rate dynamics is ~10-100 msec, it is much faster than the dynamics due 170 
to neuromodulators, which is ~sec to min (Table 1). Hence, we shall ignore the neural 171 
population dynamics and assume the system to be dominated by the slower 172 
neuromodulator induced dynamics (41). In general, different neuronal types can respond 173 
differently (in terms of firing rate activity) to the same current injection. In experiments, 174 
such relationship is demonstrated by the frequency-current (f-I) relationship. In a similar 175 
vein, we can describe the 𝑖-th neural population by the population firing rate-current (f-I) 176 
curve or input-output function (42).  177 
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𝑓𝑖 = 𝐹𝑖(𝐼𝑇𝑜𝑡𝑎𝑙,𝑖)      (1) 178 
where 𝑓𝑖 is the population firing rate, 𝐹𝑖 the input-output function, and 𝐼𝑇𝑜𝑡𝑎𝑙,𝑖 the total 179 
averaged afferent current. Under typical physiological ranges, it suffices to use a 180 
threshold-linear function (42). 181 
𝐹𝑖(𝐼𝑇𝑜𝑡𝑎𝑙,𝑖) = 𝐾𝑖  [𝐼𝑖−𝐼0,𝑖 + 𝐼𝐵𝑖𝑎𝑠,𝑖]+                 (2) 182 
where [𝑥]+ = 𝑥 if 𝑥 > 0, and 0 otherwise. 𝐾𝑖 is the constant gain or slope of the input-183 
output function, I0,i is the threshold current for non-zero firing, and IBias,i is the current 184 
coming from other brain areas. Thus, after a specific threshold value of the averaged 185 
afferent current, the neural population will be activated, and there is a linear relationship 186 
between the neural firing rate and the overall afferent current. We shall later show that this 187 
function fits the experimental data for Ox, 5-HT and NE neurons.  188 
 189 
In general, the afferent current 𝐼 𝑖 can consist of several different types of currents 190 
mediated by the different modulators and their receptor subtypes. Each of these currents 191 
will be determined by the corresponding neuromodulator concentration levels and the 192 
receptor affinities (Fig. 2). For example, suppose a neuromodulator 𝑦 from region 𝑗 induces 193 
a current 𝐼𝑗→𝑖 on target region 𝑖, then we can describe the dynamics of the current by,  194 
𝜏𝑗→𝑖  
𝑑𝐼𝑗→𝑖
𝑑𝑡
= −𝐼𝑗→𝑖 + 𝐺𝑗→𝑖([𝑦])                      (3) 195 
where [𝑦] is the neuromodulator concentration level, and 𝜏𝑗→𝑖 is the effective time constant 196 
due to the applied neuromodulator which can be estimated from experiments. (If there are 197 
more than one receptor subtypes mediated by the same neuromodulator over the same 198 
brain regions, we can specify the above variables further, e.g. by defining 𝜏𝑗→𝑖,𝑅 and 𝐼𝑗→𝑖,𝑅 199 
for a receptor subtype 𝑅.) The value of 𝜏𝑗→𝑖 can be deduced from the response dynamics 200 
of the induced current (or neural firing rates, if the induced current data is not available) 201 
upon infusion of specific neuromodulator at the targeted neurons. The input-output 202 
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function 𝐺𝑗→𝑖 can be described by the sigmoid like function commonly used in 203 
pharmacology (43):  204 
𝐺𝑗→𝑖([𝑦]) = 𝑝𝑗→𝑖,𝐿𝑅 +
𝑝𝑗→𝑖,𝑈𝑅
1+exp (−
log10([𝑦]+𝑝𝑗→𝑖,𝐿𝑆)
𝑝𝑗→𝑖,𝑆
)
     (4) 205 
where 𝑝𝑗→𝑖,𝐿𝑅 and 𝑝𝑗→𝑖,𝑈𝑅 determine the range of the neuromodulatory effect on the 206 
currents, and 𝑝𝑗→𝑖,𝐿𝑆 and 𝑝𝑗→𝑖,𝑆 control the lateral shift and the slope of the neuromodulator 207 
response current function, respectively. The values of these parameters will be fitted to 208 
experimental data through firing rate-neuromodulator concentration or firing rate-current 209 
relationships. We used the standard nonlinear regression method, nlinfit from MATLAB 210 
(The MathWorks Inc., Natick, MA, 2000). This approach particularly allows us to 211 
circumvent the complexity of actually simulating the intracellular signal transduction at the 212 
post-synaptic neurons. This post-synaptic current depends upon the extracellular 213 
neuromodulator release which is in turn dependent on the (pre-synaptic) neural population 214 
firing rate of the source neurons. Thus, to close the loop in the model, we have to 215 
mathematically describe how the release-and-reuptake dynamics are affected by the 216 
neural firing rate of the neuromodulator source. We follow a mathematical form similar to 217 
that estimated from voltammetric measurements (44):   218 
𝑑[𝑦]
𝑑𝑡
= [𝑦]𝑝,𝑗→𝑖  𝑓𝑗 −
𝑉𝑚𝑎𝑥 [𝑦]
𝐾𝑚+[𝑦]
       (5) 219 
where [𝑦]𝑝,𝑗→𝑖 is the per stimulus [𝑦] release (at the targeted area 𝑖 from source 𝑗). The 220 
rightmost term in Equation (5) represents the reuptake rate, and is approximated from the 221 
Michaelis-Menten equation. Here, 𝐾𝑚 and 𝑉𝑚𝑎𝑥 are the Michaelis-Menten constants, with 222 
𝑉𝑚𝑎𝑥 defined as the maximum uptake rate and 𝐾𝑚 the substrate concentration where the 223 
uptake proceeds at half of the maximum rate. The value for both of these parameters can 224 
be obtained from experiments (44). In voltammetry experiments, 𝑓𝑗 is typically an artificially 225 
applied high current stimulus frequency to stimulate the release of 𝑦. However, following 226 
our previous work (45), we can redefine it as the neural firing frequency of the 227 
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neuromodulator source. Hence the value of [𝑦]𝑝,𝑗→𝑖 has to be adjusted from that in 228 
voltammetry experiments, and the exact value in the model can be obtained by 229 
constraining the overall basal activity levels of the system to be within the observed 230 
experimental ranges (see below).  231 
 232 
For the case of Ox, there is a lack of available experimental data, particularly its release 233 
and reuptake dynamics. Hence we adopt the simplest mathematical form to describe the 234 
[Ox] dynamics (45), with only 2 parameters:   235 
𝑑[𝑂𝑥]
𝑑𝑡
= 𝛼 𝑓𝐿𝐻𝐴 −  𝜂 [𝑂𝑥]     (6) 236 
where 𝛼 is the rise-factor and 𝜂 a constant decay rate, and both considered to be free 237 
parameters. The value of 𝛼 is selected so that the release of [Ox-A/B] at DRN or [Ox-A] at 238 
LC is close to the observed basal value (see Table 1).  239 
  240 
A summary of the general model construction process is summarised in Fig. 2. Such a 241 
modelling approach can allow multiple brain regions to be constructed, simulated, and 242 
analysed. (See Methods for a simpler approach when only two brain regions are 243 
considered). Overall, we have proposed an efficient and scalable approach by 244 
incorporating neuromodulator properties and dynamics into traditional firing-rate type 245 
models. We shall next apply this approach to develop a neural circuit model involving 246 
multiple interacting neuromodulators.  247 
 248 
2.2. An example with three interacting neuromodulators 249 
We shall now demonstrate, as an example, the steps towards developing a neural circuit 250 
model of 3 interacting neuromodulator systems (lateral hypothalamus, dorsal raphe 251 
nucleus and locus coeruleus) through 3 corresponding neuromodulators (Ox, 5-HT and 252 
NE), based on available experimental data and Equations (1)-(6). These brain regions 253 
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were chosen mainly because: (i) they consist of different neuromodulator systems that can 254 
directly influence each other; (ii) they were targets of existing drugs, and (iii) we can 255 
demonstrate how one could model with incomplete information. It is important to bear in 256 
mind that different datasets from various experiments are used for model construction and 257 
validation.  258 
 259 
First, the frequency-current (𝑓 − 𝐼) curves for neurons from the 3 brain regions are 260 
determined according to the available electrophysiological data (𝑓 − 𝐼 curves and typical 261 
baseline firing rate ranges). Using the threshold-linear function (Equation 2), the fitted 262 
parameter values for the LC’s NE neuronal 𝑓 − 𝐼 curve are 𝑘𝐿𝐶 = 0.058 𝐻𝑧/𝑝𝐴, 𝐼0,𝐿𝐶 =263 
0.028 𝑝𝐴 and 𝐼𝐵𝑖𝑎𝑠,𝐿𝐶 = 37.41 𝑝𝐴 (46); that for DRN’s 5-HT neuron are 𝑘𝐷𝑅𝑁 =264 
0.033 𝐻𝑧/𝑝𝐴, 𝐼0,𝐷𝑅𝑁 = 0.13 𝑝𝐴 and 𝐼𝐵𝑖𝑎𝑠,𝐷𝑅𝑁 = 24.82 𝑝𝐴 (11, 47, 48); and that for LHA’s Ox 265 
neuron are 𝑘𝐿𝐻𝐴 = 0.2 𝐻𝑧/𝑝𝐴, 𝐼0,𝐿𝐻𝐴 = 0 𝑝𝐴 and 𝐼𝐵𝑖𝑎𝑠,𝐿𝐻𝐴 = 11.5 𝑝𝐴 (49). 266 
 267 
Next, parameters of the induced currents and associated 𝐺 functions are fitted to the 268 
experimental data through the concentration–response relationships for the change in 269 
firing-rate induced by the neuromodulator. For example, the total afferent current induced 270 
by neuromodulators on DRN’s neurons can be rewritten as a sum: 𝐼𝐷𝑅𝑁 = 𝐼𝐿𝐻𝐴→𝐷𝑅𝑁 +271 
𝐼𝐿𝐶→𝐷𝑅𝑁. The terms on the right are the currents due to Ox-A/B from LHA and NE from LC 272 
(for simplicity, we ignore the current due to autoreceptors and interneurons within each 273 
brain region, see (17, 50)). The dynamics for each induced current are dependent on the 274 
concentration of the neuromodulator. The Ox induced current on DRN neurons (when NE 275 
induced current on DRN is clamped) can be described by  276 
𝜏𝐿𝐻𝐴→𝐷𝑅𝑁  
𝑑𝐼𝐿𝐻𝐴→𝐷𝑅𝑁
𝑑𝑡
= −𝐼𝐿𝐻𝐴→𝐷𝑅𝑁 + 𝐺𝐿𝐻𝐴→𝐷𝑅𝑁([𝑂𝑥])   (7) 277 
where 𝜏𝐿𝐻𝐴→𝐷𝑅𝑁 is the effective time constant due to the injected Ox deduced from 278 
experiments. The 𝐺𝐿𝐻𝐴→𝐷𝑅𝑁 function (from Equation 4, with units of currents) parameters 279 
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are fitted to experimental data (51), such that 𝑝𝐿𝑅 = 0 𝑝𝐴, 𝑝𝑈𝑅 = 65 𝑝𝐴, 𝑝𝐿𝑆 = −2.08 𝑛𝑀, 280 
𝑝𝑆 = 0.452 𝑛𝑀, and 𝜏𝐿𝐻𝐴→𝐷𝑅𝑁 = 60 𝑠. With these values, we obtain the best fit for the 281 
overall firing rate-concentration function (Fig. 3A), having the induced currents becoming 282 
an implicit function.  283 
 284 
Similarly, we can obtain the parameter values for the other currents: 𝐼𝐿𝐶→𝐷𝑅𝑁, 𝐼𝐿𝐻𝐴→𝐿𝐶  and 285 
𝐼𝐷𝑅𝑁→𝐿𝐶. The fitted parameter values for 𝐼𝐿𝐶→𝐷𝑅𝑁 are 𝑝𝐿𝑅 = 0 𝑝𝐴, 𝑝𝑈𝑅 = 57 𝑝𝐴, 𝑝𝐿𝑆 =286 
−3.7 𝑛𝑀, 𝑝𝑆 = 0.193 𝑛𝑀, and 𝜏𝐿𝐶→𝐷𝑅𝑁 = 20 𝑠 (Fig. 3B)(52). Parameter values for the 287 
incoming current from LHA to LC neurons 𝐼𝐿𝐻𝐴→𝐿𝐶 are found to be 𝑝𝐿𝑅 = 3.8 𝑝𝐴, 𝑝𝑈𝑅 =288 
54 𝑝𝐴, 𝑝𝐿𝑆 = −2.3 𝑛𝑀, 𝑝𝑆 = 0.341 𝑛𝑀, and 𝜏𝐿𝐻𝐴→𝐿𝐶 = 20 𝑠 (36) (Fig. 3C). For 289 
IDRNLC: 𝑝𝐿𝑅 = 0 𝑝𝐴, 𝑝𝑈𝑅 = 40 𝑝𝐴, 𝑝𝐿𝑆 = 4.214 𝑛𝑀, 𝑝𝑆 = 0.347 𝑛𝑀, and 𝜏𝐷𝑅𝑁→𝐿𝐶 = 20 𝑠  290 
(Fig. 3D). With these parameter values, we were able to obtain reasonable fits with respect 291 
to experiments for the various input-output functions.   292 
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 293 
We now proceed to model the effects of 5-HT on LC’s NE neurons. However there is a 294 
lack of experimental data on the direct effects of 5-HT on LC’s NE neurons (experiments 295 
typically focused on how different 5-HT2 receptor agonists affect the firing rate of LC 296 
neurons (53)). Thus to estimate the 5-HT dependent input-output function of firing 297 
frequency, we approximate the input-output function from other experimental data by 298 
restricting the basal activities to [5 − 𝐻𝑇]~ 0.11 𝑓𝑀 And 𝑓𝐿𝐶  ~ 2.15 𝐻𝑧 (see Table I). We 299 
considered the same sigmoidal shape (as defined in Eq. 4) for all the neuromodulator 300 
dependent firing-rate function which is defined as follows:  301 
 302 
                                  𝐻𝑗→𝑖([𝑦]) = 𝑞𝑗→𝑖,𝐿𝑅 +
𝑞𝑗→𝑖,𝑈𝑅
1+exp (−
log10([𝑦]+𝑞𝑗→𝑖,𝐿𝑆)
𝑞𝑗→𝑖,𝑆
)
                                  (8) 303 
 
 
 
Figure 3. Fitted input-output functions. (A-B) Effects of concentrations [Ox-
A/B] and [5-HT] on DRN neurons. (C-D) [5-HT] and [NE] on LHA neurons. (E-F) 
[Ox-A] and [5-HT] on LC neurons. Estimated function (pink) is based on f-I curves 
and current input-output functions.  
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where 𝑞𝑗→𝑖,𝐿𝑅 and 𝑞𝑗→𝑖,𝑈𝑅 determine the range of the neuromodulatory effect on the firing-304 
rate, and 𝑞𝑗→𝑖,𝐿𝑆 and 𝑞𝑗→𝑖,𝑆 control the lateral shift and the slope of the neuromodulator 305 
concentration dependent firing-rate function 𝐻𝑗→𝑖, respectively. Considering these baseline 306 
values, the estimated parameter values are 𝑞𝐿𝑅 = 2.15 𝐻𝑧, 𝑞𝑈𝑅 = −2.15 𝐻𝑧, 𝑞𝐿𝑆 =307 
4.273 𝑛𝑀 and 𝑞𝑆 = 0.3 𝑛𝑀 (54).   308 
 309 
Similar to the 5-HT modulating effect on LC, the 5-HT response direct firing frequency 310 
curve was not available for LHA neurons. Thus, we approximate the input-output function 311 
from other experimental data (38, 55) and restricting the basal activities to 312 
[5 − 𝐻𝑇]~ 1.6 𝑛𝑀 and 𝑓𝐿𝐻𝐴 ~ 2.3 𝐻𝑧. Then the estimated parameter values are 𝑞𝐿𝑅 =313 
2.3 𝐻𝑧, 𝑞𝑈𝑅 = −2.3 𝐻𝑧, 𝑞𝐿𝑆 = 0.9 𝑛𝑀, 𝑞𝑆 = 0.1 𝑛𝑀 (37). Then we approximated the 314 
parameters for 𝐼𝐷𝑅𝑁→𝐿𝐻𝐴 to be: 𝑝𝐿𝑅 = 0 𝑝𝐴, 𝑝𝑈𝑅 = 36 𝑝𝐴, 𝑝𝐿𝑆 = −1.55 𝑛𝑀, and 𝑝𝑆 =315 
0.4 𝑛𝑀. With these values, we observe that there is no Ox neuronal firing even for 10 M 316 
of [5-HT] (Fig. 3E). This is due to the strong inhibition caused by the induced inward GIRK 317 
current (~32 pA), which eventually saturates (at ~35 pA) for higher [5-HT] levels.  318 
 319 
As the model has a hard threshold in the f-I curve, there is a sharp change within the 10 −320 
100 𝑛𝑀 of [5-HT]. Thus, we could not obtain a perfect fit for the functions 321 
𝐺𝐷𝑅𝑁→𝐿𝐻𝐴([5 − 𝐻𝑇]) and hence the 𝑓𝐿𝐻𝐴 − [5 − 𝐻𝑇] curve. Similarly, the fitted parameters 322 
for the NE induced GIRK currents on LHA, 𝐼𝐿𝐶→𝐿𝐻𝐴, are 𝑝𝐿𝑅 = 0 𝑝𝐴, 𝑝𝑈𝑅 = 120 𝑝𝐴, 𝑝𝐿𝑆 =323 
−5.39 𝑛𝑀, 𝑝𝑆 = 0.4 𝑛𝑀 and 𝜏𝐿𝐶→𝐿𝐻𝐴 = 1𝑠 (56). We encounter a similar issue for higher 324 
[NE] level, i.e. no perfect fit for 𝐺𝐿𝐶→𝐿𝐻𝐴([5 − 𝐻𝑇]) (Fig. 3F).  325 
 326 
Compared to the effect of 5-HT on the target areas, estimating the parameter values (q’s) 327 
for the effect of NE/Ox on the target areas was relatively straight forward. As experimental 328 
data related to neuromodulator dependent firing-rate input-output function was available. 329 
We approximated the q values for the Ox effect of DRN as 𝑞𝐿𝑅 = 0.8 𝐻𝑧, 𝑞𝑈𝑅 = 2.2 𝐻𝑧, 330 
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𝑞𝐿𝑆 = −2.072 𝑛𝑀, 𝑞𝑆 = 0.4463 𝑛𝑀 (36). q values for the Ox effect of LC are 𝑞𝐿𝑅 = 2.35 𝐻𝑧, 331 
𝑞𝑈𝑅 = 3.15 𝐻𝑧, 𝑞𝐿𝑆 = −2.3066 𝑛𝑀, 𝑞𝑆 = 0.3468 𝑛𝑀 (36). Similarly q values for the NE 332 
effect of LHA  are  estimated as 𝑞𝐿𝑅 = 2.3 𝐻𝑧, 𝑞𝑈𝑅 = −2.3 𝐻𝑧, 𝑞𝐿𝑆 = −4.235 𝑛𝑀, 𝑞𝑆 =333 
0.302 𝑛𝑀 (56). For NE effect on DRN are 𝑞𝐿𝑅 = 0.8 𝐻𝑧, 𝑞𝑈𝑅 = 0.193 𝐻𝑧, 𝑞𝐿𝑆 = −3.711 𝑛𝑀, 334 
𝑞𝑆 = 0.208 𝑛𝑀 (39). 335 
 336 
After determining the input-output functions and dynamics for all the currents, the final step 337 
is to integrate all three brain regions and their interactions. In general, the activities for the 338 
combined system will be different from the individual isolated systems. Thus, the baseline 339 
activities of the coupled system will be different from that observed from the individual 340 
systems. However, the remaining set of parameters, the neuromodulator release per-341 
stimulus frequencies, i.e. the [𝑦]𝑝′𝑠 can be adjusted to resolve this. We found that for 342 
values of [5 − 𝐻𝑇]𝑝,𝐿𝐻𝐴, [5 − 𝐻𝑇]𝑝,𝐿𝐶, [𝑁𝐸]𝑝,𝐷𝑅𝑁 , and [𝑁𝐸]𝑝,𝐿𝐻𝐴 at 12.14 𝑛𝑀, 0.852 𝑓𝑀, 343 
27.272 𝑛𝑀 and 0.0642 𝑛𝑀, respectively, and Ox rise-factor and decay rate (  and ) for 344 
DRN are 1.405 and 0.85 1/s while for LC are 0.2314 𝑛𝑀 and 0.85 1/𝑠, the overall basal 345 
firing rates and concentration levels are reasonably within the experimental ranges (Table 346 
I). Note that the baseline activities are obtained after sufficiently long simulation to attain 347 
their (stable) steady states (see Fig. 4 for a sample trial).  348 
 349 
After successfully constructing the LHA-DRN-LC circuit model, we shall demonstrate 350 
simulating neuropharmacological drug effects in the system. In particular, we shall focus 351 
on Ox-1 receptor antagonist (SB-334867-A), SSRIs and/or SNRIs on the LHA-DRN-LC 352 
circuit.  353 
 354 
 355 
 356 
 357 
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 358 
Figure 4. Single trial activity dynamics under baseline condition. (A) Firing-rate of 359 
DRN neural population. (B, C) Concentration level of 5-HT in the LHA and LC areas. 360 
 361 
2.3. Drug effect simulations 362 
Pharmacologically, antagonists can be classified into two categories, competitive and 363 
irreversible antagonists (57). Pre-treatment or application of competitive antagonist can 364 
shift the baseline dose response curve horizontally. This shift towards the higher doses (of 365 
neurotransmitter) increases the effective dose (ED50) value of the dose-response curve 366 
(where 50% of the maximal response of the dose is being observed). Conversely, 367 
application of an irreversible antagonist can cause shifts in the maximum range of the 368 
antagonist effect and does not affect the ED50 value (58).  369 
 370 
Ox-1 receptor antagonists have been suggested to encourage sleep, as well as treatment 371 
and prevention of many psychiatric disorders (59). In particular, the Ox-1 receptor 372 
antagonist, SB-334867-A, acts as a competitive antagonist which rightward shifts the Ox-373 
A response curve in 5-HT and NE neurons in DRN and LC (36, 60). Thus, we can easily 374 
incorporate the effect of SB-334867-A, by simply laterally shifting the function 375 
𝐺𝐿𝐻𝐴→𝐷𝑅𝑁/𝐿𝐶  ([𝑂𝑥 − 𝐴] ).  376 
 377 
Selective serotonin/norepinephrine reuptake inhibitors (SSRIs/NRIs) are some of the 378 
commonly known pharmacological agents that are used for the treatment of various 379 
psychiatric disorders. The basic (acute) actions of these drugs are similar: primarily to 380 
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increase the extracellular concentration level of their respective neuromodulator 381 
concentration by inhibiting the uptake process and reduce the synaptic clearance in the 382 
extracellular space (61). There have been numerous studies conducted to understand the 383 
effects of uptake inhibitors on [5-HT] uptake (61, 62). In particular, John et al. (62) shows 384 
that monoamine uptake inhibitors can affect the values of the Michaelis-Menten constants 385 
Km and Vmax in the limbic part of the brain. For example, a 10 𝜇𝑀 of fluoxetine, a SSRI 386 
(when applied to the substantia nigra area) increased the value of 𝐾𝑚 by about a factor of 387 
5 but did not alter the value of Vmax significantly (61). Thus, to incorporate the influence of 388 
SSRIs/NRIs in our model, we can mimic the different doses of SSRIs by varying the 389 
different values of Km. For simplicity, our model will ignore chronic or other long-term 390 
secondary actions such as receptor density changes.  391 
 392 
As we increase the value of 𝐾𝑚,[5−𝐻𝑇] (mimic SSRI), [5 − 𝐻𝑇] linearly increases in both the 393 
targeted areas LHA and LC (Figs. 5A and H, solid blue). This increase in [5-HT] level 394 
causes a significant decrease in 𝑓𝐿𝐻𝐴 (Fig. 5C, solid blue), which is consistent with 395 
experimental findings (37). This in turn causes a decrease in [Ox-A/B] levels in the DRN 396 
and LC areas (Figs. 5D and G, solid blue). Interestingly, because of the network effect, 397 
there is a subsequent decrease in 𝑓𝐷𝑅𝑁 (Fig. 5F, solid blue), consistent with (63) even 398 
when we did not incorporate any inhibitory 5-HT autoreceptors (64, 65). However, 5-HT’s 399 
effect on LC’s NE neurons is minimal, consistent with (66), and therefore 𝑓𝐿𝐶 does not alter 400 
the [NE] levels in the DRN and LHA significantly (Fig. 5I, solid blue). These effects 401 
remained to be validated in the intact brain.  402 
 403 
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 404 
 405 
Figure 5. Effects of substrate concentration factor 𝑲𝒎,[𝟓−𝑯𝑻] and 𝑲𝒎,[𝑵𝑬], and [𝑶𝒙 −406 
𝑨] antagonist SB-334867-A on the firing rates and concentration levels in the circuit. 407 
Each panel varies both 𝐾𝑚,[5−𝐻𝑇] and 𝐾𝑚,[𝑁𝐸] values to simulate the effects of drugs and 408 
their combinations. 𝐾𝑚,[𝑁𝐸] = 400 𝑛𝑀 (control basal value).  409 
 410 
Next, we simulate the combined effects of SSRIs and NRIs, by increasing the value of 411 
𝐾𝑚,[𝑁𝐸] to 3 and 5 times its control value (400 𝑛𝑀) while varying Km, [5-HT] as previously. The 412 
model shows that for higher values of 𝐾𝑚,[𝑁𝐸] more [5-HT] and [NE] are released in the 413 
targeted areas in the LHA and LC as compared to controls (Figs. 5A and H, dashed red 414 
and dotted-dashed pink). This suggests that other than 𝐾𝑚,[5−𝐻𝑇], [NE] release in DRN 415 
also helps stimulate the release of [5-HT] in these targeted areas, consistent with (67). 416 
This rise in the [5-HT] level significantly affects 𝑓𝐿𝐻𝐴, [𝑂𝑥 − 𝐴/𝐵]𝐷𝑅𝑁, [𝑂𝑥 − 𝐴]𝐿𝐶, [𝑁𝐸]𝐷𝑅𝑁 417 
and [𝑁𝐸]𝐿𝐻𝐴 while there is little impact on 𝑓𝐿𝐶 (Figs. 5B-E, G and I).  418 
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Finally, to assess the combined effect of SSRIs, NRIs and SB-334867-A, we set 𝐾𝑚,[𝑁𝐸] to 419 
be 5 times the control value and mimic the influence of 10 𝜇𝑀 SB-334867-A on DRN and 420 
LC (by changing the 𝑝𝐿𝑅 value from 3.8 to 2 𝑝𝐴, 𝑝𝑈𝑅 from 54 to 51 𝑝𝐴, shift factor 𝑝𝐿𝑆 from 421 
−2.3 to −4.192 𝑛𝑀, and slope factor 𝑝𝑆 from 0.341 to 0.592 in LC). For DRN, 𝑝𝐿𝑆 is changed 422 
from −2.08 𝑛𝑀 to −2.97 𝑛𝑀 and 𝑝𝑆 from 0.452 to 0.367. We find that this triple-drug 423 
combination can cause a further decrease in the 𝑓𝐷𝑅𝑁 and 𝑓𝐿𝐶, and a substantial reduction 424 
in [𝑁𝐸]𝐷𝑅𝑁 levels (Figs. 5E-F and I, solid green), while the rest are not significantly affected 425 
by the addition of SB-334867-A (Figs. 5A-D, G-H, solid green).  426 
 427 
2.4. Software for model simulation and visualization 428 
Using MATLAB, we have designed and developed a software, called “NModC” 429 
(Neuromodulator circuit), with friendly graphical user interface (GUI) for simulation, 430 
analysis and visualization of the types of models described. The software is easy to use, 431 
and can easily be generalized to additional brain regions, other neural sub-populations, 432 
and neuromodulator types. The user can visualize the activities of multiple brain regions 433 
dynamically and simultaneously. These brain regions are embedded in a rotatable 3-D 434 
glass brain using standard Montreal Neurological Institute (MNI) coordinates (Fig. 6A). The 435 
user can also further specify brain regions of interest to find the dynamical variables’ time 436 
courses and mutual relationships (Fig. 6B) for more detailed analysis. The model 437 
parameters can be easily altered to visualize the variation in the steady-state values of the 438 
transients of neuromodulator concentration level and firing-rates, and can also compare 439 
the firing-rates of the two brain regions (Fig. 6C). Further details are described in the 440 
Methods section and the software is available at 441 
https://github.com/vyoussofzadeh/NModC.  442 
 443 
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 444 
 445 
Figure 6. Screenshot of the NModC software. A user friendly GUI of neuromodulator 446 
neural circuit model that can simulate, analyse, visualize and edit. (A) Users can run the 447 
model to visualize the results within a rotatable 3-D glass brain after pressing the ‘Start’ 448 
button. The user can stop the simulation using the ‘Stop’ button. Simulation time 449 
parameters can be controlled using ‘Time’ and ‘Sim scale’, and the GUI can be closed 450 
using ‘Close’ buttons. (B) Model variables’ time courses and their mutual relationships can 451 
be observed using the ‘Outputs’ button. (C) Model variables’ exact values can be found 452 
and model parameters edited upon pressing the ‘Parameters’ button. ‘Default’ returns to 453 
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default model parameters and ‘Simulate’ re-run the model after editing the parameter 454 
values.  455 
 456 
3. Discussion 457 
In this work, we have proposed a new computational modelling framework for 458 
incorporating essential biological features of neuromodulation in neural circuits. This 459 
provides a computational platform to link from low-level neurobiology to large-scale brain 460 
activities.  461 
 462 
Our framework is based on the population averaged firing-rate type of model which have 463 
model parameters constrained by neurobiology. This is to be compared to other firing rate 464 
type models without such constraints (14-16). The model integrates pharmacological and 465 
electrophysiological data from separate experimental studies to constrain the input-output 466 
neuronal functions, and also the timescale and profile of the effective neuromodulator 467 
induced currents. Another key difference in our modelling approach is the consideration of 468 
the release-and-reuptake/decay dynamics of the extracellular neuromodulator 469 
concentration level which can be inferred from voltammetry. By doing this, we 470 
circumvented modelling the complex intracellular biochemical processes, but instead, 471 
directly modelled the concentration dependent effect on neural firing rate activity based on 472 
pharmacological-electrophysiological data.  473 
 474 
In particular, to allow our approach to be generalizable to multiple interacting brain regions, 475 
we introduced neuromodulator induced currents to bridge the gaps between 476 
neuromodulator concentration levels and targeted neural firing rate activities – afferent 477 
influences from different brain regions can be accounted by their summed currents. The 478 
timescale and response curve of the neuromodulator concentration dependent currents 479 
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were constrained by data from combined pharmacological and electrophysiological 480 
experiments.  481 
 482 
We demonstrated our modelling approach with the example of a neural circuit that involves 483 
three mutually interacting brain regions (LHA, DRN and LC), which are also sources of 484 
three different neuromodulators: orexin, serotonin and norepinephrine respectively. The 485 
transient and steady-state dynamics of the experimentally measurable variables (neural 486 
firing rates and neuromodulators’ extracellular concentration levels) could be easily 487 
simulated. In particular, our model supported the co-existence of the observed (steady-488 
state) baseline firing rates and neuromodulator levels found in separate experiments.  489 
 490 
An important application of our model was the prediction of the effects of 491 
neuropharmacological drugs on neural circuits. We simulated the effects of SSRIs, NRIs 492 
and Ox-1 receptor antagonist on the LHA-DRN-LC model. We first showed that SSRIs 493 
could have a wide effect on the neural circuit, except the LC-NE system. Interestingly, 494 
SSRI could inhibit the DRN (decrease in fDRN), the source of 5-HT, even though we did not 495 
implement its inhibitory autoreceptors. This effect was essentially due to the direct effects 496 
on serotonin heteroreceptors on the LHA and LC, which in turn inhibited the DRN. Similar 497 
circuit-based effects could be explained for the addition of NRIs and/or Ox-1 receptor 498 
antagonists.  499 
 500 
The constructed LHA-DRN-LC circuit model turned out to be dominated by a unidirectional 501 
influence between any pair of interacting brain areas (Fig. 5). Hence, these result in 502 
monotonic relationships (either increased or decreased) as the model parameters (e.g. 503 
𝐾𝑚′𝑠) were varied. However, this need not generally be the case. For example, a more 504 
balanced (especially excitatory-inhibitory) coupled network could easily lead to emergent 505 
circuit oscillations or even non-monotonic effects (8, 68). In the latter case, it might then 506 
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be possible to search for the optimal drug dosage. In fact, we had shown evidence of such 507 
nonlinear emergent behaviour when the model incorporated autoreceptors and non-508 
principal (e.g. inhibitory GABAergic) interneurons (to mediate indirect connections) (17). 509 
Moreover, the excitatory-inhibitory balance of the network can also be influenced by the 510 
co-release of the neurotransmitters (e.g. glutamate) (69, 70). In this case, our framework 511 
can still accommodate this by introducing additional dynamical equations to describe the 512 
effects of glutamate or GABA (for the same pre-synaptic firing rate).  513 
 514 
Our work has also shown that administration of multiple drugs (serotonin/norepinephrine 515 
reuptake inhibitors and Ox-A antagonist) simultaneously can be simulated in neural circuits 516 
to search for the optimal mixture of drugs. However, the results remain to be validated as 517 
there is a lack of such work done in experiments. Hence, this will form model predictions 518 
that can help experimentalists in designing future studies. For example, multi-electrode 519 
array (MEA) in-vivo recordings can be designed to study the wide-ranging effects of drugs 520 
on different brain areas. It would also be interesting to use the model to minimize the side 521 
effects of drugs, which is an important issue in neuropharmacology.  522 
 523 
Our modelling framework is scalable to incorporate multiple brain regions and hence can 524 
be used to study large-scale brain effects. This includes studying the changes in REM/non-525 
REM stages or sleep-wake cycle (15, 16), cortical dynamics (8), and cognitive-emotional 526 
processing (8, 68). This would require extending our current GUI software by including 527 
cortical brain structure and their connectivity with the neuromodulator sources. Thus these 528 
models could potentially reveal insights into the relationships among various brain and 529 
behavioural disorders (depression, addiction, antidepressants, and sleep disorders). 530 
Importantly, neuroimaging data, especially from positron emission tomography and 531 
functional magnetic resonance imaging (fMRI), could potentially be incorporated into our 532 
modelling framework, bridging across multiple scales and modalities, similar in spirit to the 533 
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popular dynamic causal modelling approach (71). Interestingly, recent whole brain 534 
molecular imaging (functional MRI) of serotonin transporter to characterise 5-HT dynamics 535 
in humans before and after (e.g. SSRI) drug administration is now possible (72), opening 536 
up another possible application of our modelling framework.  537 
 538 
In summary, we have proposed a promising new computational modelling framework that 539 
can integrate various experimental neurobiological data into a computationally efficient 540 
large-scale neural circuit model for simulating, testing and predicting the effects of multiple 541 
endogenous neuromodulators and neuropharmacological drugs.  542 
 543 
4. Methods 544 
A simpler modelling approach for modelling two brain regions. Note that if one is only 545 
interested in the mutual interactions of two brain regions, then one may ignore the induced 546 
current implementation step (Fig. 2, second column), and directly model the influence of 547 
[𝑦] on the firing rates 𝑓𝑖 (45), i.e.  548 
𝜏𝑗→𝑖  
𝑑𝑓𝑖
𝑑𝑡
= −𝑓𝑖 + 𝐾𝑖([𝑦])      (9) 549 
where 𝜏𝑗→𝑖 is the effective time constant due to the injected neuromodulator 𝑦 on the 𝑖-th 550 
neural population. 𝐾𝑖([𝑦]) can follow a similar form as the 𝐺 function in Eqn. (4).  551 
 552 
Model parameter and baseline values. A summary of the LHA-DRN-LC model 553 
parameter values and baseline activities are shown in the table below.  554 
 555 
Table 1. Basal firing rate, neurotransmitter levels, dynamical time constants, and other 556 
model parameters for the LHA-DRN-LC circuits. 557 
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Asterisk: (73), Assuming Vmax, and per stimulus release at dorsal lateral geniculate (DLG) 558 
and LC will be same, # : (44), + : Parameter values are tuned to obtain the basal values 559 
close to those in experiments. 560 
Parameter Description Value Reference, remarks 
fDRN Basal firing rate of 5-HT neurons in DRN 0.8 Hz (74), in vitro 
fLC Basal firing rate of NE neurons in LC 2.15 Hz  (54), in vitro 
fLHA Basal firing rate of Ox neurons in LHA 2.3 Hz  (38), in vitro 
kLHA Gain of the input-output function for LHA neurons 0.2 Hz/pA (49) 
KDRN Gain of the input-output function for DRN neurons 0.033 Hz/pA (11, 47, 48) 
kLC Gain of the input-output function for LC neurons 0.058 Hz/pA (46) 
I0,LHA Threshold current for non-zero firing of LHA neurons 0 pA (49) 
I0,DRN Threshold current for non-zero firing of DRN neurons 24.82 pA (11, 47, 48) 
I0,LC Threshold current for non-zero firing of LC neurons 0.028 pA (46) 
      IBIAS,LHA Afferent current to LHA neurons 11.5 pA (49) 
IBIAS,DRN Afferent current to DRN neurons 24.82 pA (11, 47, 48) 
IBIAS,LC Afferent current to LC neurons 37.41 pA (46) 
[5-HT]LHA Basal [5-HT] level in Ox neurons 1.6 nM (55) 
[5-HT]LC Basal [5-HT] level in Ne neurons 6.7 fM/min 
~0.11 fM/s 
(75) 
[NE]DRN Basal [NE] level in 5-HT neurons  500 pg/mg 
 ~2.95 M 
(76), assuming baseline  
5-HT  levels at dorsal and 
rostral raphe are same. 
[NE]LHA Basal [NE] level in Ox neurons 0.83 nM (77), assuming baseline NE 
 levels at hypothalamus and 
 LHA are the same. 
[Ox]DRN Basal [Ox] level in 5-HT neurons 
 
10 pg/mg 
       ~3.4 nM 
(78), assuming baseline Ox 
 level at pons and DRN are  
 the same. 
[Ox]LC Basal [Ox] level in Ne neurons  
 
2 pg/mg 
0.56 nM 
(78) 
[5-HT]LHA Time constant of the effect of [5-HT] on Ox neurons 2 s (37) 
[5-HT]LC Time constant of  the effect of [5-HT] on Ne neurons                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        20 s       (79)
[Ox]DRN Time constant of the effect of [Ox] on 5-HTneurons  60 s (51) 
[Ox]LC Time constant of the effect of [Ox] on Ne neurons 20 s (80) 
[NE]DRN Time constant of the effect of [NE] on 5-HT neurons  20 s (52) 
[NE]LHA Time constant of the effect of [NE] on Ox neurons 1 s (56) 
Vmax, [NE]LC Maximum uptake rate for the [NE] release in LC neurons 74 nM/s  
Km, [NE]LC Substrate concentration for the [NE] release in LC  
Neurons 
400 nM  
Vmax, [NE]DRN Maximum uptake rate for the [NE] release in DRN 
 neurons 
74 nM/s  
Km, [NE]DRN Substrate concentration for the [NE] release in DRN 
 neurons 
400 nM  
Vmax, [NE]LHA Maximum uptake rate for the [NE] release in LHA in 
 neurons 
74 nM/s  
Km, [NE]LHA Substrate concentration for the [NE] release in LHA in 
 neurons 
400 nM  
Vmax, [5-HT]DRN Maximum uptake rate for the [5-HT] release in DRN 
 neurons 
1800 nM/s  
Km, [5-HT]DRN Substrate concentration for the [5-HT] release in DRN  
neurons 
170 nM  
Vmax, [5-HT]LHA Maximum uptake rate for the [5-HT] release in LHA 
 neurons 
1800 nM/s  
Km, [5-HT]LHA Substrate concentration for the [5-HT] release in LHA 
 neurons 
170 nM  
Vmax, [5-HT]LC Maximum uptake rate for the [5-HT] release in LC  
neurons 
1800 nM/s  
Km, [5-HT]LC Substrate concentration for the [5-HT] release in LC 
 neurons 
170 nM  
[Ox]LC Rise factor for [Ox] release in LC neurons 0.2314 nM  
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[Ox]LC Decay rate for [Ox] release in LC neurons 0.85/s  
[Ox]DRN Rise factor for [Ox] release in DRN neurons 1.405 nM  
[Ox]DRN Decay rate for [Ox] release in DRN neurons 0.85/s  
[5-HT]p, LHA Per-stimulus [5-HT] release in LHA neurons 12.14 nM  
[5-HT]p, LC Per-stimulus [5-HT] release in LC neurons 0.852 fM   
[NE]p, DRN Per-stimulus [NE] release in DRN neurons 27.272 nM  
[NE]p, LHA Per-stimulus [NE] release in LHA neurons 0.0642 nM   
 561 
Numerical simulations. The neural circuit model simulation for the interaction of the three 562 
brain areas is computed by using the forward Euler numerical integration method which is 563 
applied to the set of the first-order differential equations. A time step of 1 millisecond was 564 
used. Smaller time steps were tested without affecting the results. These simulations can 565 
also be extended to other (e.g. 2nd order or 4th order Runge-Kutta) numerical schemes. 566 
Simulations were run till stable steady states are obtained.  567 
 568 
GUI software. To begin the software, the user presses the ‘Start’ button on the starting 569 
window of the GUI. This will result in the model outputs of the interacting brain regions 570 
(Fig. 6A). The outputs appear in the form of normalized neural (firing rate) at the specified 571 
brain regions, e.g. red colour represents relatively higher activity while blue colour 572 
represents lower activity. The range of the colour map is based on the absolute range of 573 
[0 255] Hz. These colours of activity can change over time, reflecting their dynamics. The 574 
regions are embedded in locations based on the Montreal Neurological Institute (MNI) 575 
coordinates in a glass brain. 3-D rotation of the brain is also allowed in the software. 576 
Although the structure of the glass brain is currently based on a normal human MRI data, 577 
it can be easily replaced by an animal (e.g. rodent) glass brain using the appropriate brain 578 
atlas.  579 
 580 
Once the model is converged after simulation, upon clicking on the “Outputs” button in the 581 
starting window, the dynamical variables for the selected regions will appear in a new 582 
window (Fig. 6B). The variables are the (absolute) neural firing rates and neuromodulator 583 
concentrations of the selected brain regions. Both the individual variable’s temporal 584 
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dynamics and mutual relationships between the variables can be plotted. Upon clicking 585 
the ‘Parameters’ button in the starting window, a new window appear in which the model 586 
parameter values and the initial numerical values of the variables are shown. The model 587 
parameter values can be edited within this window. Once this is done, the user can re-588 
simulate the new model by pressing the ‘Simulate’ button within the same window. This 589 
generates the transients of baseline firing rates and concentration levels and shows the 590 
relationship among them (e.g. firing-rates). For default values, all the transient activities 591 
eventually attain their stable steady-states. These steady-state values of the system 592 
parameters varies as we change the model parameters. For example, to mimic the 593 
complex drug effects of SSRI’s, Km is varied and corresponding changes in the steady-594 
state values are analysed separately (see Section 2.3). If a mistake is made, the user can 595 
always retrieve back the initial values of the parameters by clicking on the ‘Default’ button.  596 
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 826 
 827 
Figure legends 828 
Figure 1. Interactions among three brain regions, which are sources of 829 
neuromodulators. LHA: lateral hypothalamus; DRN: dorsal raphe nucleus; LC: locus 830 
coeruleus. Ox: orexin; 5-HT: serotonin. Arrows: effective excitatory connections between 831 
any two areas; circles: inhibitory connections. Different colours denote different brain 832 
areas. Small fonts denote receptor subtypes at the target sites (35-39).  833 
 834 
Figure 2. Incorporating afferent currents from neuromodulator concentration levels. 835 
[𝑦1] … [𝑦𝑛] denote the different neuromodulator concentrations. 𝑖 represents a particular 836 
targeted brain region. 𝐼𝑗→𝑖 is the corresponding induced currents to region 𝑖. 𝐼𝑇𝑜𝑡𝑎𝑙,𝑖 is the 837 
total afferent current and 𝑓𝑖 is the firing frequency in region 𝑖. For example, [𝑦1] and [𝑦2] 838 
may be the concentration levels of serotonin [5 − 𝐻𝑇] and norepinephrine [𝑁𝐸], and 𝑖 can 839 
be the lateral hypothalamus LHA. The big arrow denotes “closing the loop” in the modelling 840 
process.  841 
  842 
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Figure 3. Fitted input-output functions. (A-B) Effects of concentrations [Ox-A/B] and 843 
[NE] on DRN neurons. (C-D) [Ox-A] and [5-HT] on LC neurons. (E-F) [5-HT] and [NE] on 844 
LHA neurons. Estimated function (pink) is based on f-I curves and current input-output 845 
functions. 846 
 847 
Figure 4. Single trial activity dynamics under baseline condition. (A) Firing-rate of 848 
DRN neural population. (B, C) Concentration level of 5-HT in the LHA and LC areas. 849 
 850 
Figure 5. Effects of substrate concentration factor 𝑲𝒎,[𝟓−𝑯𝑻] and 𝑲𝒎,[𝑵𝑬], and [𝑶𝒙 − 𝑨] 851 
antagonist SB-334867-A on the firing rates and concentration levels in the circuit. 852 
Each panel varies both 𝐾𝑚,[5−𝐻𝑇] and 𝐾𝑚,[𝑁𝐸] values to simulate the effects of drugs and 853 
their combinations. 𝐾𝑚,[𝑁𝐸] = 400 𝑛𝑀 (control basal value).  854 
 855 
Figure 6. Screenshot of the NModC software. A user friendly GUI of neuromodulator 856 
neural circuit model that can simulate, analyse, visualize and edit. (A) Users can run the 857 
model to visualize the results within a rotatable 3-D glass brain after pressing the ‘Start’ 858 
button. The user can stop the simulation using the ‘Stop’ button. Simulation time 859 
parameters can be controlled using ‘Time’ and ‘Sim scale’, and the GUI can be closed using 860 
‘Close’ buttons. (B) Model variables’ time courses and their mutual relationships can be 861 
observed using the ‘Outputs’ button. (C) Model variables’ exact values can be found and 862 
model parameters edited upon pressing the ‘Parameters’ button. ‘Default’ returns to default 863 
model parameters and ‘Simulate’ re-run the model after editing the parameter values.  864 
 865 
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Table legends 866 
Table 1. Basal firing rate, neurotransmitter levels, dynamical time constants, and other 867 
model parameters for the LHA-DRN-LC circuits. 868 
 869 
 870 
